Next-Gen Diagnostics for CKM & CKD Management and Therapy Development

Cardio-kidney-metabolic (CKM) diseases, like diabetes, hypertension, and chronic kidney disease (CKD), affect >40% of the global population. These diseases frequently interact – when kidney injury is in play, it drives high morbidity, mortality & healthcare costs. Clinicians and Pharma still lack practical early diagnostics to identify, stratify, and manage early kidney injury, as well as to develop and monitor nephroprotective therapies, leaving ~90% kidney injury cases in a blind spot.

With >15-year's research in mice, dogs & humans and validation across multiple nephropathies, we are developing RenoRisk, a novel urinary biomarker panel, that originate from and can readily measure the early subtle injury of the kidney. The test enables a 3-6 years’ earlier time window for reversible interventions and can also monitor treatment effect without time lag.

Benchmarking HbA1C test for diabetes and lipid tests for cardiovascular diseases, the emerging market for early and prognosis kidney biomarkers is valued to be 5-10B$, spanning primary and specialty care. Our market traction was confirmed by the strong partnership with the renowned nephrologists across Europe and China.

We are currently raising 2M USD for product development, regulatory preparation, and early Go-To-Market with Pharma and Biotech for clinical trial applications.